Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04936724 · ClinicalTrials.gov registry record · NA

FDA Cigarette Warning Labels: Eye Tracking Study

A NA study of Smoking, Cigarette, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT04936724 is a NA study of Smoking, Cigarette that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 70 participants, below the 531-participant average among 21 other Smoking, Cigarette trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04936724, a NA study of Smoking, Cigarette, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the effect of cigarette pictorial warning label content (lesser-known vs well-known risks) on visual engagement, recall, and knowledge of tobacco use harms.

Conditions Studied

Interventions

  • OTHER Pictorial Warning Labels

Study Locations (1)

Pennsylvania

  • Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2020-12-22
Est. Completion 2021-11-19
Phase NA

What the Registry Record Tells You About NCT04936724

The ClinicalTrials.gov registry entry for NCT04936724 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 531-participant average among 21 other Smoking, Cigarette trials with a reported enrollment target (87% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking, Cigarette appearing as the primary indexed condition, and to 1 intervention - of which Pictorial Warning Labels is the first listed.

NCT04936724 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04936724 about?

NCT04936724 is a clinical study titled "FDA Cigarette Warning Labels: Eye Tracking Study". The purpose of this study is to examine the effect of cigarette pictorial warning label content (lesser-known vs well-known risks) on visual engagement, recall, and knowledge of tobacco use harms.

What is the current status of trial NCT04936724?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2020-12-22. Estimated completion is 2021-11-19.

What conditions does trial NCT04936724 study?

This clinical trial studies the following conditions: Smoking, Cigarette.

What interventions are being tested in trial NCT04936724?

The interventions under investigation include: Pictorial Warning Labels (OTHER).

Who is sponsoring clinical trial NCT04936724?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04936724 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking, Cigarette

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.